Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 14.
doi: 10.1002/ejhf.70006. Online ahead of print.

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Jishnu Malgie #  1 , Mariëlle I Wilde #  1 , Stefan Koudstaal  1   2 , Robert Denham  3 , Carlos A da Fonseca  4 , Henk P Swart  5 , Clara E E van Ofwegen  6 , Ayten Yilmaz  7 , Ron Pisters  8 , Gerard C M Linssen  9 , Nikola Faber  10 , Loek van Heerebeek  11 , Julio E C van de Swaluw  12 , Rudolf A de Boer  1 , Hans-Peter Brunner-La Rocca  13   14 , Jasper J Brugts  1
Affiliations

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Jishnu Malgie et al. Eur J Heart Fail. .

Abstract

Aims: Guideline-recommended medical therapy (GRMT) improves outcomes in heart failure (HF) with reduced ejection fraction (HFrEF), yet implementation remains suboptimal. TITRATE-HF prospectively evaluated GRMT implementation across different HFrEF stages, and its effect on 1-year prognosis and left ventricular ejection fraction (LVEF).

Methods and results: TITRATE-HF is an observational cohort study across 48 hospitals in the Netherlands (June 2022-February 2024). A total of 4288 patients were enrolled. This primary analysis includes 12-month follow-up data of all HFrEF patients (n = 3367), stratified into de novo, chronic, and worsening HF. Longitudinal trends in GRMT prescription rates and dosages were analysed. Serial echocardiographic data assessed changes in LVEF between baseline and 12 months. Kaplan-Meier analysis assessed the composite endpoint of all-cause death or HF hospitalization. Median age was 71 years (interquartile range [IQR] 63-78), 29% were female, and 56% had non-ischaemic cardiomyopathy. In de novo HFrEF (n = 1353), quadruple therapy was 47.2% at 6 weeks, 64.7% at 3 months, 69.5% at 6 months, and 64.4% at 12 months. In chronic/worsening HFrEF (n = 1625), quadruple therapy increased from 44.6% at baseline to 54.6% at 12 months, primarily driven by greater sodium-glucose co-transporter 2 inhibitor uptake (66.0% to 78.5%). Among de novo HFrEF patients with serial echocardiograms (n = 752), median LVEF improved by 10% (IQR 3-17%) in ischaemic versus 15% (IQR 9-24%) in non-ischaemic cardiomyopathy (p < 0.001). Early quadruple GRMT initiation (within 6 weeks) and higher 6-month doses were associated with greater LVEF improvement. At 12 months, the composite endpoint occurred in 13.3%, 13.3%, and 43.8% of de novo, chronic, and worsening HFrEF patients, respectively.

Conclusions: These findings highlight the importance of early and intensive GRMT implementation, and emphasize the need for continuous dose titration beyond the initial phase to improve LVEF and clinical outcomes.

Keywords: Guidelines; Implementation; Pharmacotherapy; Registry; Titration.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2024;26:5–17. https://doi.org/10.1002/ejhf.3024
    1. Brunner‐La Rocca HP, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma HJ, Westendorp PH, et al.; CHECK‐HF Investigators. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: The CHECK‐HF Registry. JACC Heart Fail 2019;7:13–21. https://doi.org/10.1016/j.jchf.2018.10.010
    1. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP‐HF Registry. J Am Coll Cardiol 2018;72:351–366. https://doi.org/10.1016/j.jacc.2018.04.070
    1. Malgie J, Clephas PRD, Brunner‐La Rocca HP, de Boer RA, Brugts JJ. Guideline‐directed medical therapy for HFrEF: sequencing strategies and barriers for life‐saving drug therapy. Heart Fail Rev 2023;28:1221–1234. https://doi.org/10.1007/s10741‐023‐10325‐2

LinkOut - more resources